Versant Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.3K Hold
689
– – ﹤0.01% 1904
2026
Q2
$25.6K Hold
689
– – ﹤0.01% 1811
2026
Q1
$21.9K Buy
689
+37
+6% +$1.01K ﹤0.01% 1770
2025
Q4
$17.7K Buy
652
+438
+205% +$11.5K ﹤0.01% 1718
2025
Q3
$5.54K Hold
214
– – ﹤0.01% 2172
2025
Q2
$4.36K Buy
214
+126
+143% +$2.45K ﹤0.01% 2206
2025
Q1
$1.6K Buy
+88
New +$1.97K ﹤0.01% 2301
2024
Q4
– Sell
-92
Closed -$3.13K – 2386
2024
Q3
$3.13K Buy
+92
New +$3.5K ﹤0.01% 1432

Other funds holding CLDX

Versant Capital Management's CLDX Position: Q3 2026 in Review

Versant Capital Management held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 689 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1904.

Versant Capital Management first reported a position in CLDX in Q3 2024 and has held it in 8 quarters since. The position peaked at $25.6K in Q2 2026. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Versant Capital Management held 689 shares of Celldex Therapeutics worth $22.3K as of Q3 2026.
  • Versant Capital Management left its Celldex Therapeutics share count unchanged in Q3 2026.
  • Celldex Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1904 holding.
  • Versant Capital Management first reported a position in Celldex Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Versant Capital Management's Celldex Therapeutics position peaked at $25.6K in Q2 2026.
  • 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.